$RLBD
Real Brands Inc

2023 Q4 Form 10-Q Financial Statement

#000126493123000066 Filed on November 17, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $17.96K
YoY Change 565.19%
Cost Of Revenue $0.00 $47.36K
YoY Change
Gross Profit $17.96K -$47.36K
YoY Change 565.19% -5847.57%
Gross Profit Margin 100.0%
Selling, General & Admin $139.4K $150.0K
YoY Change 27.82% -33.8%
% of Gross Profit 776.06%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $22.47K $20.62K
YoY Change 8.97% 0.0%
% of Gross Profit 125.11%
Operating Expenses $160.0K $147.0K
YoY Change 23.4% -35.12%
Operating Profit -$142.0K -$194.4K
YoY Change 11.88% -13.9%
Interest Expense -$16.38K -$10.00K
YoY Change 41.7% 20.92%
% of Operating Profit
Other Income/Expense, Net -$3.550K
YoY Change
Pretax Income -$162.0K -$230.0K
YoY Change 16.93% -9.68%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$162.0K $229.4K
YoY Change 16.93% -190.07%
Net Earnings / Revenue -901.84%
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 2.691B shares 2.691B shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $79.35K $0.00
YoY Change 2684.21% -100.0%
Cash & Equivalents $79.35K $987.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $79.35K $987.00
YoY Change 2107.09% -88.14%
LONG-TERM ASSETS
Property, Plant & Equipment $1.075M $1.096M
YoY Change -7.12% -7.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $125.0K $130.0K
YoY Change
Other Assets $530.00 $0.00
YoY Change 0.0% -100.0%
Total Long-Term Assets $1.201M $1.221M
YoY Change 3.67% 3.61%
TOTAL ASSETS
Total Short-Term Assets $79.35K $987.00
Total Long-Term Assets $1.201M $1.221M
Total Assets $1.280M $1.222M
YoY Change 10.18% 2.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $472.00 $570.0K
YoY Change -79.18% 0.48%
Accrued Expenses $930.9K $865.7K
YoY Change 37.84% 40.96%
Deferred Revenue
YoY Change
Short-Term Debt $952.8K $840.0K
YoY Change 61.05% 58.91%
Long-Term Debt Due $25.04K $30.00K
YoY Change
Total Short-Term Liabilities $2.505M $2.346M
YoY Change 40.03% 37.19%
LONG-TERM LIABILITIES
Long-Term Debt $78.72K $82.79K
YoY Change -37.34% -36.98%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $78.72K $82.79K
YoY Change -37.34% -36.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.505M $2.346M
Total Long-Term Liabilities $78.72K $82.79K
Total Liabilities $2.584M $2.429M
YoY Change 34.95% 31.9%
SHAREHOLDERS EQUITY
Retained Earnings -$13.91M -$13.74M
YoY Change 10.6% 10.53%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.304M -$1.206M
YoY Change
Total Liabilities & Shareholders Equity $1.280M $1.222M
YoY Change 10.18% 2.96%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$162.0K $229.4K
YoY Change 16.93% -190.07%
Depreciation, Depletion And Amortization $22.47K $20.62K
YoY Change 8.97% 0.0%
Cash From Operating Activities -$27.80K -$20.00K
YoY Change -88.15% -125.69%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $5.000K -$130.0K
YoY Change
Cash From Investing Activities $5.000K -$130.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 109.3K 20.00K
YoY Change -52.28% -125.48%
NET CHANGE
Cash From Operating Activities -27.80K -20.00K
Cash From Investing Activities 5.000K -130.0K
Cash From Financing Activities 109.3K 20.00K
Net Change In Cash 86.50K -130.0K
YoY Change -1678.47% 19900.0%
FREE CASH FLOW
Cash From Operating Activities -$27.80K -$20.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001084133
CY2022Q4 us-gaap Investments
Investments
usd
CY2022Q4 us-gaap Short Term Non Bank Loans And Notes Payable
ShortTermNonBankLoansAndNotesPayable
usd
CY2023Q3 us-gaap Revenues
Revenues
usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
usd
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
usd
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
usd
CY2023Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
usd
CY2022Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
usd
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
usd
us-gaap Loss Contingency Accrual Carrying Value Period Increase Decrease
LossContingencyAccrualCarryingValuePeriodIncreaseDecrease
usd
us-gaap Increase Decrease In Payable For Investment Purchased
IncreaseDecreaseInPayableForInvestmentPurchased
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Certain Loans Acquired In Transfer Accounted For As Debt Securities Accretable Yield Disposals Of Loans
CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesAccretableYieldDisposalsOfLoans
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2023Q3 us-gaap Amount Of Impairment To Carrying Amount Of Regulatory Assets
AmountOfImpairmentToCarryingAmountOfRegulatoryAssets
usd
CY2022Q4 us-gaap Amount Of Impairment To Carrying Amount Of Regulatory Assets
AmountOfImpairmentToCarryingAmountOfRegulatoryAssets
usd
CY2021Q4 RLBD Extended Maturity Date
ExtendedMaturityDate
P2Y
CY2023Q4 RLBD Additioanl Extended Maturity Date
AdditioanlExtendedMaturityDate
P2Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-24115
dei Entity Registrant Name
EntityRegistrantName
REAL BRANDS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
40-0014655
dei Entity Address Address Line1
EntityAddressAddressLine1
12 Humbert Street
dei Entity Address City Or Town
EntityAddressCityOrTown
North Providence
dei Entity Address State Or Province
EntityAddressStateOrProvince
RI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02911
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
803-0004
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2690640226 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
987 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2845 usd
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
750 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
987 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3595 usd
CY2023Q3 us-gaap Deposits
Deposits
530 usd
CY2022Q4 us-gaap Deposits
Deposits
530 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1095880 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1157734 usd
CY2023Q3 us-gaap Investments
Investments
125000 usd
CY2023Q3 us-gaap Assets
Assets
1222397 usd
CY2022Q4 us-gaap Assets
Assets
1161859 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
566399 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
476543 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
865687 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
675349 usd
CY2023Q3 us-gaap Loans Payable Current
LoansPayableCurrent
215672 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
75000 usd
CY2023Q3 us-gaap Loans Payable
LoansPayable
384605 usd
CY2022Q4 us-gaap Loans Payable
LoansPayable
273605 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
200000 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
200000 usd
CY2023Q3 us-gaap Notes Payable
NotesPayable
43003 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
43003 usd
CY2023Q3 us-gaap Short Term Non Bank Loans And Notes Payable
ShortTermNonBankLoansAndNotesPayable
25040 usd
CY2023Q3 us-gaap Discontinued Operation Amounts Of Material Contingent Liabilities Remaining
DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining
45625 usd
CY2022Q4 us-gaap Discontinued Operation Amounts Of Material Contingent Liabilities Remaining
DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining
45625 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2346031 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1789125 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
82792 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
125629 usd
CY2023Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Long Term Debt
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
82792 usd
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Long Term Debt
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
125629 usd
CY2023Q3 us-gaap Liabilities
Liabilities
2428823 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1914754 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3998000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3998000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2690640226 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2690640226 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2690640226 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2690640226 shares
CY2023Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
2690640 usd
CY2022Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
2690640 usd
CY2023Q3 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
6806011 shares
CY2022Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
6806011 shares
CY2023Q3 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
96403 usd
CY2022Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
96403 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9751471 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9034617 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13744940 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12574555 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1206426 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-752895 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1222397 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1161859 usd
us-gaap Revenues
Revenues
42497 usd
us-gaap Revenues
Revenues
8434 usd
CY2022Q3 us-gaap Revenues
Revenues
824 usd
us-gaap Revenues
Revenues
42497 usd
us-gaap Revenues
Revenues
8434 usd
CY2022Q3 us-gaap Revenues
Revenues
824 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
85610 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7507 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
47360 usd
us-gaap Gross Profit
GrossProfit
-43113 usd
us-gaap Gross Profit
GrossProfit
927 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
-47360 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
824 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
798056 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
280862 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
84261 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
54509 usd
us-gaap Professional Fees
ProfessionalFees
60000 usd
us-gaap Professional Fees
ProfessionalFees
89400 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
19000 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
65500 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
168561 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
315686 usd
CY2023Q3 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
43750 usd
CY2022Q3 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
106574 usd
us-gaap Operating Expenses
OperatingExpenses
1026617 usd
us-gaap Operating Expenses
OperatingExpenses
685948 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
147011 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
226583 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1069730 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-685021 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-194371 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-225759 usd
us-gaap Depreciation
Depreciation
61854 usd
us-gaap Depreciation
Depreciation
61458 usd
CY2023Q3 us-gaap Depreciation
Depreciation
20618 usd
CY2022Q3 us-gaap Depreciation
Depreciation
20618 usd
us-gaap Interest Expense Other
InterestExpenseOther
38801 usd
us-gaap Interest Expense Other
InterestExpenseOther
20945 usd
CY2023Q3 us-gaap Interest Expense Other
InterestExpenseOther
14376 usd
CY2022Q3 us-gaap Interest Expense Other
InterestExpenseOther
8271 usd
us-gaap Other Income
OtherIncome
-100655 usd
us-gaap Other Income
OtherIncome
-82403 usd
CY2023Q3 us-gaap Other Income
OtherIncome
-34994 usd
CY2022Q3 us-gaap Other Income
OtherIncome
-28890 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1170385 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-767424 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-229365 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-254649 usd
us-gaap Net Income Loss
NetIncomeLoss
1170385 usd
us-gaap Net Income Loss
NetIncomeLoss
767424 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
229365 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
254649 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2690640226 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2677563303 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2690640226 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2677630564 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-11951 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
60205 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
266105 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-217851 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
65000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
246672 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-339522 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
254649 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
654169 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-752895 usd
CY2023Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
595445 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
752577 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-910027 usd
CY2023Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
60373 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
188443 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1038097 usd
CY2023Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
61036 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
229365 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1206426 usd
us-gaap Net Income Loss
NetIncomeLoss
1170385 usd
us-gaap Net Income Loss
NetIncomeLoss
767424 usd
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
716854 usd
us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
61854 usd
us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
61458 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
750 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
898 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
280194 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
258763 usd
us-gaap Loss Contingency Accrual Carrying Value Period Increase Decrease
LossContingencyAccrualCarryingValuePeriodIncreaseDecrease
-45625 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-110733 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-491930 usd
us-gaap Increase Decrease In Payable For Investment Purchased
IncreaseDecreaseInPayableForInvestmentPurchased
-125000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-125000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
140672 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
75000 usd
us-gaap Increase Decrease In Notes Payable Related Parties Current
IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
111000 usd
us-gaap Increase Decrease In Notes Payable Related Parties Current
IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
120000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
17797 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
17187 usd
us-gaap Certain Loans Acquired In Transfer Accounted For As Debt Securities Accretable Yield Disposals Of Loans
CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesAccretableYieldDisposalsOfLoans
60205 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
65000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
233875 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
303018 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1858 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-188936 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2845 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
197255 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
987 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8319 usd
us-gaap Interest Paid
InterestPaid
5088 usd
us-gaap Interest Paid
InterestPaid
5681 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1000 usd
us-gaap Net Income Loss
NetIncomeLoss
1170385 usd
us-gaap Net Income Loss
NetIncomeLoss
767424 usd
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
987 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2845 usd
CY2023Q3 us-gaap Capital
Capital
2345044 usd
CY2022Q4 us-gaap Capital
Capital
1808830 usd
CY2023Q3 RLBD Capital Increase Decrease
CapitalIncreaseDecrease
536214 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_842_eus-gaap--UseOfEstimates_z0nlbvNZ0OZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of estimates and judgments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Key areas of estimation include the estimated useful lives of property, plant, equipment and intangibles assets and liabilities, income taxes, and the valuation of stock-based compensation. Due to the uncertainty inherent in such estimates, actual results may differ from the Company’s estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2023Q3 us-gaap Derivative Instruments In Hedges Liabilities At Fair Value
DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_z9ynIQPfUipa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Concentrations of Credit Risk</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p>
CY2020Q1 RLBD Shares Issued Of Aquisition Company
SharesIssuedOfAquisitionCompany
2000000 shares
CY2020Q1 RLBD Mortgage Assumption
MortgageAssumption
189916 usd
CY2021Q4 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
475000 usd
CY2021Q4 RLBD Year Of Depreciation For Improvements
YearOfDepreciationForImprovements
P15Y
us-gaap Depreciation And Amortization
DepreciationAndAmortization
22563 usd
CY2021Q4 RLBD Year Of Depreciation For Improvements
YearOfDepreciationForImprovements
P15Y
us-gaap Other Real Estate Non Covered Period Increase Decrease
OtherRealEstateNonCoveredPeriodIncreaseDecrease
39291 usd
us-gaap Depreciation
Depreciation
61854 usd
CY2023Q3 us-gaap Option Indexed To Issuers Equity Indexed Shares
OptionIndexedToIssuersEquityIndexedShares
300173307 shares
CY2023Q3 us-gaap Ownshare Lending Arrangement Shares Outstanding
OwnshareLendingArrangementSharesOutstanding
31496498 shares
CY2022Q3 us-gaap Option Indexed To Issuers Equity Indexed Shares
OptionIndexedToIssuersEquityIndexedShares
154518887 shares
CY2022Q3 us-gaap Ownshare Lending Arrangement Shares Outstanding
OwnshareLendingArrangementSharesOutstanding
29752495 shares
us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
50%
CY2023Q3 us-gaap Accounts Receivable Gross
AccountsReceivableGross
0 usd
CY2021Q4 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
475000 usd
CY2021Q4 RLBD Year Of Depreciation For Improvements
YearOfDepreciationForImprovements
P15Y
us-gaap Depreciation And Amortization
DepreciationAndAmortization
22563 usd
CY2021Q4 RLBD Year Of Depreciation For Improvements
YearOfDepreciationForImprovements
P15Y
us-gaap Other Real Estate Non Covered Period Increase Decrease
OtherRealEstateNonCoveredPeriodIncreaseDecrease
39291 usd
us-gaap Depreciation
Depreciation
61854 usd
CY2023Q3 us-gaap Inventory Buildings And Improvements
InventoryBuildingsAndImprovements
475000 usd
CY2022Q4 us-gaap Inventory Buildings And Improvements
InventoryBuildingsAndImprovements
475000 usd
CY2023Q3 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
785823 usd
CY2022Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
785823 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1260823 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1260823 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
164943 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
103089 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1095880 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1157734 usd
CY2023Q3 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
2206 shares
CY2023Q3 us-gaap Investments
Investments
125000 usd
CY2023Q3 us-gaap Investment Owned Percent Of Net Assets
InvestmentOwnedPercentOfNetAssets
0.02 pure
CY2023Q3 RLBD Real Brand Granted Distribution
RealBrandGrantedDistribution
0.03 pure
CY2023Q3 us-gaap Investment Company Equity Security Fv Ni Contractual Sale Restriction Remaining Period
InvestmentCompanyEquitySecurityFvNiContractualSaleRestrictionRemainingPeriod
P3Y
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P20D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
0 shares
CY2015Q4 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
71069 usd
CY2018Q4 RLBD Officer Base Salary
OfficerBaseSalary
175000 usd
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
865687 usd
CY2023Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
56350 usd
CY2023Q3 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
200000 usd
srt Mortgage Loans On Real Estate Interest Rate
MortgageLoansOnRealEstateInterestRate
0.0631 pure
us-gaap Interest Paid
InterestPaid
5088 usd
CY2023Q3 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.07 pure
CY2023Q3 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.07 pure
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
716854 usd
us-gaap Increase Decrease In Due To Other Related Parties
IncreaseDecreaseInDueToOtherRelatedParties
200000 usd
CY2021Q4 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.07 pure
CY2023Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.008139
CY2023Q3 RLBD Percentage Own Converted1
PercentageOwnConverted1
0.01 pure
us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
1000000 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.05
us-gaap Interest Expense
InterestExpense
56350 usd
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2690640226 shares
CY2023Q1 us-gaap Option Indexed To Issuers Equity Indexed Shares
OptionIndexedToIssuersEquityIndexedShares
6143628 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease
500000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
94654420 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.007
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.007
us-gaap Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense
DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
716854 usd
us-gaap Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense
DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
0 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
61036 usd

Files In Submission

Name View Source Status
0001264931-23-000066-index-headers.html Edgar Link pending
0001264931-23-000066-index.html Edgar Link pending
0001264931-23-000066.txt Edgar Link pending
0001264931-23-000066-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
real10q32023.htm Edgar Link pending
report.css Edgar Link pending
rlbd-20230930.xsd Edgar Link pending
rlbd-20230930_cal.xml Edgar Link unprocessable
real10q32023_htm.xml Edgar Link completed
Show.js Edgar Link pending
rlbd-20230930_def.xml Edgar Link unprocessable
rlbd-20230930_pre.xml Edgar Link unprocessable
rlbd-20230930_lab.xml Edgar Link unprocessable